THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [5.4] ID: TIP-MED-000072

Rabeprazole Sodium

Active Ingredient / Scientific Identity: Rabeprazole Sodium • Class: Proton Pump Inhibitor (Non-Enzymatically Metabolised Benzimidazole PPI)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Rabeprazole Sodium ([5.4] | ID: TIP-MED-000072) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/5-4-rabeprazole-sodium/
Generic / Entity NameRabeprazole Sodium ([5.4])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassProton Pump Inhibitor (Non-Enzymatically Metabolised Benzimidazole PPI)
Available Dosage FormsEnteric-Coated Tablets: 10 mg, 20 mg; IV Injection: 20 mg
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: No dose adjustment needed. Hepatic: Use with caution in severe hepatic impairment (Child-Pugh C).
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Rabeprazole Sodium (TIP-MED-000072, Reference Code [5.4]) is classified under Gastrointestinal & Hepatobiliary Medicines (Ch 05) as a Proton Pump Inhibitor (Non-Enzymatically Metabolised Benzimidazole PPI). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 05 [5.4], p. 61): Razo (Dr. Reddy's), Rablet (Lupin), Veloz (Torrent), Hapifast, Cyra; In FDC with Domperidone: Razo-D, Rablet-D, Veloz-D; With Levosulpiride: Razo-L (Caution in elderly!) — Strengths & Dosage Forms: Enteric-Coated Tablets: 10 mg, 20 mg; IV Injection: 20 mg
Representative Indian Market Examples (Edition 2.7 Ch 05 [5.4], p. 61): Razo (Dr. Reddy's), Rablet (Lupin), Veloz (Torrent), Hapifast, Cyra; In FDC with Domperidone: Razo-D, Rablet-D, Veloz-D; With Levosulpiride: Razo-L (Caution in elderly!) — Strengths & Dosage Forms: Enteric-Coated Tablets: 10 mg, 20 mg; IV Injection: 20 mg
Dosage Forms & Available Strengths:
Enteric-Coated Tablets: 10 mg, 20 mg; IV Injection: 20 mg
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Proton Pump Inhibitor (Non-Enzymatically Metabolised Benzimidazole PPI) acting on target receptor/enzyme pathways in Gastrointestinal & Hepatobiliary Medicines (Ch 05): clinical efficacy is mediated via Proton Pump Inhibitor (Non-Enzymatically Metabolised Benzimidazole PPI) for GERD; erosive oesophagitis; duodenal and gastric ulcers; H. pylori eradication; gastroprotection with antiplatelets/NSAIDs..

4. Therapeutic Indications & Evidence-Supported Uses

  • GERD
  • erosive oesophagitis
  • duodenal and gastric ulcers
  • pylori eradication
  • gastroprotection with antiplatelets/NSAIDs

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: 20 mg once daily (10 mg OD for maintenance; 20 mg BD for H. pylori eradication). Follow physician prescription.

Administration & Meal Timing: Take 30 minutes BEFORE breakfast on an empty stomach. Swallow enteric-coated tablet whole. | Once daily in the morning before breakfast.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: No dose adjustment needed. Hepatic: Use with caution in severe hepatic impairment (Child-Pugh C).
Elimination & Renal Adjustment:
Renal: No dose adjustment needed. Hepatic: Use with caution in severe hepatic impairment (Child-Pugh C).
Hepatic Impairment Considerations:
Renal: No dose adjustment needed. Hepatic: Use with caution in severe hepatic impairment (Child-Pugh C).

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Same class precautions as pantoprazole (exclude gastric cancer if alarm symptoms exist; monitor long-term users for hypomagnesaemia, fractures, B12 malabsorption, and AIN).

Key Clinical Precautions: Renal: No dose adjustment needed. Hepatic: Use with caution in severe hepatic impairment (Child-Pugh C).

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Headache, diarrhoea, pharyngitis, flatulence, abdominal pain.
  • Acute interstitial nephritis, severe hypomagnesaemia, C. difficile colitis, thrombocytopenia/neutropenia (rare).
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Metabolised predominantly via non-enzymatic thioether reduction with minimal CYP2C19 involvement—therefore safe to use alongside Clopidogrel (like pantoprazole), phenytoin, and warfarin! Still causes gastric pH-dependent malabsorption of ketoconazole, itraconazole, cefpodoxime, cefuroxime axetil, and iron

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Rabeprazole achieves rapid first-day acid suppression when taken 30 minutes before breakfast. Critical Warning on '-L' Combinations (Rabeprazole + Levosulpiride, e.g., Razo-L / Veloz-L): Warn elderly patients never to take Rabeprazole + Levosulpiride combinations long-term (>4–8 weeks), as levosulpiride blocks central D2 receptors and is a leading cause of severe drug-induced Parkinsonism (resting tremor, rigidity, shuffling gait) in elderly Indians!
  • Meal & Clock Timing Instruction: Take 30 minutes BEFORE breakfast on an empty stomach. Swallow enteric-coated tablet whole. (Once daily in the morning before breakfast.)
  • Missed Dose Protocol: Take 30 minutes before the next meal on the same day; skip if close to next morning.
  • Geriatric Dispensing Pearl: Plain Rabeprazole 20 mg is safe and has minimal CYP2C19 interactions in polypharmacy, but always screen out prolonged use of Rabeprazole + Levosulpiride (-L) or Rabeprazole + Domperidone (-D) FDCs in the elderly.

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Enteric-Coated Tablets: 10 mg, 20 mg; IV Injection: 20 mg

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 05 [5.4] (p. 61)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/5-4-rabeprazole-sodium/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.